Arriving in the field of excess body fat therapy, retatrutide is a different strategy. Beyond many available medications, retatrutide functions as a twin agonist, simultaneously targeting both GLP-like peptide-1 (GLP-1) and glucose-sensitive insulinotropic hormone (GIP) binding sites. This dual engagement fosters multiple advantageous effects, such